277 related articles for article (PubMed ID: 16304269)
41. Costs associated with shorter duration of antibiotic therapy in hospitalized patients with mild-to-moderate severe community-acquired pneumonia.
Opmeer BC; El Moussaoui R; Bossuyt PM; Speelman P; Prins JM; de Borgie CA
J Antimicrob Chemother; 2007 Nov; 60(5):1131-6. PubMed ID: 17827142
[TBL] [Abstract][Full Text] [Related]
42. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
Shorr AF; Khashab MM; Xiang JX; Tennenberg AM; Kahn JB
Respir Med; 2006 Dec; 100(12):2129-36. PubMed ID: 16730170
[TBL] [Abstract][Full Text] [Related]
43. Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: Results from a claims analysis.
Hess G; Hill JW; Raut MK; Fisher AC; Mody S; Schein JR; Chen CC
Adv Ther; 2010 Oct; 27(10):743-55. PubMed ID: 20799007
[TBL] [Abstract][Full Text] [Related]
44. An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin/sulbactam in hospitalized patients with community-acquired pneumonia.
Todisco T; Dal Farra F; Ciliberti G; Pirina P; Guelfi R; Serra G; Paris R; Mancuso I; Cepparulo M
J Chemother; 2008 Apr; 20(2):225-32. PubMed ID: 18467250
[TBL] [Abstract][Full Text] [Related]
45. Levofloxacin in the treatment of community-acquired pneumonia.
Noreddin AM; Elkhatib WF
Expert Rev Anti Infect Ther; 2010 May; 8(5):505-14. PubMed ID: 20455679
[TBL] [Abstract][Full Text] [Related]
46. [A pharmacoeconomic study of in-hospital treatment against community-acquired pneumonia].
Bermejo Vicedo T; Torralba Arranz A; Hidalgo Correas FJ; Millán Santos I; Rodríguez Morradan B
Farm Hosp; 2004; 28(1):29-35. PubMed ID: 15012176
[TBL] [Abstract][Full Text] [Related]
47. A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
Feagan BG
Pharmacotherapy; 2001 Jul; 21(7 Pt 2):89S-94S. PubMed ID: 11446524
[TBL] [Abstract][Full Text] [Related]
48. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital.
Feldman RB; Rhew DC; Wong JY; Charles RA; Goetz MB;
Arch Intern Med; 2003 Jul; 163(14):1718-26. PubMed ID: 12885688
[TBL] [Abstract][Full Text] [Related]
49. [Treatment for Legionnaires' disease. Macrolides or quinolones?].
Falcó V; Molina I; Juste C; Crespo M; Almirante B; Pigrau C; Ferrer A; Bravo C; Palomar M; Pahissa A
Enferm Infecc Microbiol Clin; 2006; 24(6):360-4. PubMed ID: 16792936
[TBL] [Abstract][Full Text] [Related]
50. Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia.
Goldstein LH; Gabin A; Fawaz A; Freedberg NA; Schwartz N; Elias M; Saliba W
Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1042-8. PubMed ID: 26238864
[TBL] [Abstract][Full Text] [Related]
51. [Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalization].
Geijo Martínez MP; Díaz de Tuesta Chow-Quan AM; Herranz CR; Gómez Criado C; Dimas Nuñez JF; Saiz García F
An Med Interna; 2002 Dec; 19(12):621-5. PubMed ID: 12593029
[TBL] [Abstract][Full Text] [Related]
52. Potential for cost-savings in the care of hospitalized low-risk community-acquired pneumonia patients in China.
Zhou QT; He B; Zhu H
Value Health; 2009; 12(1):40-6. PubMed ID: 18637052
[TBL] [Abstract][Full Text] [Related]
53. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin.
Palmer CS; Zhan C; Elixhauser A; Halpern MT; Rance L; Feagan BG; Marrie TJ
Clin Ther; 2000 Feb; 22(2):250-64. PubMed ID: 10743984
[TBL] [Abstract][Full Text] [Related]
54. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults.
D'Ignazio J; Camere MA; Lewis DE; Jorgensen D; Breen JD
Antimicrob Agents Chemother; 2005 Oct; 49(10):4035-41. PubMed ID: 16189077
[TBL] [Abstract][Full Text] [Related]
55. Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms.
Goldstein RC; Husk G; Jodlowski T; Mildvan D; Perlman DC; Ruhe JJ
Am J Infect Control; 2014 May; 42(5):539-41. PubMed ID: 24773792
[TBL] [Abstract][Full Text] [Related]
56. Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia.
Marrie TJ
Chemotherapy; 2004; 50 Suppl 1():11-5. PubMed ID: 15319549
[TBL] [Abstract][Full Text] [Related]
57. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
Sánchez F; Mensa J; Martínez JA; García E; Marco F; González J; Marcos MA; Soriano A; Torres A
Clin Infect Dis; 2003 May; 36(10):1239-45. PubMed ID: 12746768
[TBL] [Abstract][Full Text] [Related]
58. Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience.
Dartois N; Castaing N; Gandjini H; Cooper A;
J Chemother; 2008 Oct; 20 Suppl 1():28-35. PubMed ID: 19036672
[TBL] [Abstract][Full Text] [Related]
59. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia.
Norrby SR; Petermann W; Willcox PA; Vetter N; Salewski E
Scand J Infect Dis; 1998; 30(4):397-404. PubMed ID: 9817522
[TBL] [Abstract][Full Text] [Related]
60. A clinical pathway for community-acquired pneumonia: an observational cohort study.
Frei CR; Bell AM; Traugott KA; Jaso TC; Daniels KR; Mortensen EM; Restrepo MI; Oramasionwu CU; Ruiz AD; Mylchreest WR; Sikirica V; Raut MR; Fisher A; Schein JR
BMC Infect Dis; 2011 Jul; 11():188. PubMed ID: 21733161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
